ID   PA2TI_NAJHH             Reviewed;          48 AA.
AC   P0DUG4;
DT   07-APR-2021, integrated into UniProtKB/Swiss-Prot.
DT   07-APR-2021, sequence version 1.
DT   03-MAY-2023, entry version 9.
DE   RecName: Full=Phospholipase A2 TI-Nh {ECO:0000303|PubMed:19622365};
DE            Short=svPLA2;
DE            EC=3.1.1.4 {ECO:0000269|PubMed:19622365};
DE   AltName: Full=Phosphatidylcholine 2-acylhydrolase;
DE   AltName: Full=Thrombin inhibitor from Naja haje {ECO:0000303|PubMed:19622365};
DE   Flags: Fragments;
OS   Naja haje haje (Egyptian cobra).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Lepidosauria; Squamata; Bifurcata; Unidentata; Episquamata; Toxicofera;
OC   Serpentes; Colubroidea; Elapidae; Elapinae; Naja.
OX   NCBI_TaxID=8642;
RN   [1]
RP   PROTEIN SEQUENCE, FUNCTION, SUBCELLULAR LOCATION, SUBUNIT, CATALYTIC
RP   ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, AND MASS SPECTROMETRY.
RC   TISSUE=Venom;
RX   PubMed=19622365; DOI=10.1016/j.toxicon.2009.07.011;
RA   Osipov A.V., Filkin S.Y., Makarova Y.V., Tsetlin V.I., Utkin Y.N.;
RT   "A new type of thrombin inhibitor, noncytotoxic phospholipase A2, from the
RT   Naja haje cobra venom.";
RL   Toxicon 55:186-194(2010).
CC   -!- FUNCTION: Phospholipase A2 with weak enzymatic activity, which
CC       partially inhibits thrombin enzymatic activity (Ki=73 nM), completely
CC       inhibits thrombin-induced platelet aggregation and retards fibrin clot
CC       formation (IC(50)=0.2 nM) (PubMed:19622365). May exert this
CC       anticoagulant effect through a non-enzymatic mechanism
CC       (PubMed:19622365). {ECO:0000269|PubMed:19622365}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a 1,2-diacyl-sn-glycero-3-phosphocholine + H2O = a 1-acyl-sn-
CC         glycero-3-phosphocholine + a fatty acid + H(+); Xref=Rhea:RHEA:15801,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:28868,
CC         ChEBI:CHEBI:57643, ChEBI:CHEBI:58168; EC=3.1.1.4;
CC         Evidence={ECO:0000255|PROSITE-ProRule:PRU10035, ECO:0000255|PROSITE-
CC         ProRule:PRU10036, ECO:0000269|PubMed:19622365};
CC   -!- COFACTOR:
CC       Name=Ca(2+); Xref=ChEBI:CHEBI:29108; Evidence={ECO:0000250};
CC       Note=Binds 1 Ca(2+) ion. {ECO:0000250};
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         Vmax=0.0012 umol/min/mg enzyme (from PMID:25522251);
CC   -!- SUBUNIT: Monomer. {ECO:0000269|PubMed:19622365}.
CC   -!- SUBCELLULAR LOCATION: Secreted {ECO:0000269|PubMed:19622365}.
CC   -!- TISSUE SPECIFICITY: Expressed by the venom gland.
CC       {ECO:0000305|PubMed:19622365}.
CC   -!- MASS SPECTROMETRY: Mass=14340; Method=MALDI;
CC       Evidence={ECO:0000269|PubMed:19622365};
CC   -!- MISCELLANEOUS: Negative results: does not exert detectable effects on
CC       both the intrinsic and extrinsic pathways of the coagulation cascade
CC       (up to 50 nM) (PubMed:19622365). Does not hydrolyze either fibrinogen
CC       or thrombin (PubMed:19622365). Does not have impact on already formed
CC       fibrin clot (PubMed:19622365). Is not toxic to PC12 tumor cells (up to
CC       15 uM), but evokes neurite outgrowth in these cells (1 uM)
CC       (PubMed:19622365). Has not effect on ADP-induced platelet aggregation
CC       (PubMed:19622365). {ECO:0000269|PubMed:19622365}.
CC   -!- MISCELLANEOUS: The active site (His-25) is not easily accessible for
CC       modification by 4-bromophenacyl bromide (BPB).
CC       {ECO:0000269|PubMed:19622365}.
CC   -!- SIMILARITY: Belongs to the phospholipase A2 family. Group I subfamily.
CC       D49 sub-subfamily. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   AlphaFoldDB; P0DUG4; -.
DR   SMR; P0DUG4; -.
DR   GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0004623; F:phospholipase A2 activity; IEA:UniProtKB-EC.
DR   GO; GO:0090729; F:toxin activity; IEA:UniProtKB-KW.
DR   GO; GO:0050482; P:arachidonic acid secretion; IEA:InterPro.
DR   GO; GO:0006644; P:phospholipid metabolic process; IEA:InterPro.
DR   Gene3D; 1.20.90.10; Phospholipase A2 domain; 1.
DR   InterPro; IPR036444; PLipase_A2_dom_sf.
DR   InterPro; IPR033113; PLipase_A2_His_AS.
DR   SUPFAM; SSF48619; Phospholipase A2, PLA2; 1.
DR   PROSITE; PS00118; PA2_HIS; 1.
PE   1: Evidence at protein level;
KW   Blood coagulation cascade inhibiting toxin; Calcium;
KW   Direct protein sequencing; Disulfide bond; Hemostasis impairing toxin;
KW   Hydrolase; Metal-binding; Platelet aggregation inhibiting toxin; Secreted;
KW   Toxin.
FT   CHAIN           1..48
FT                   /note="Phospholipase A2 TI-Nh"
FT                   /evidence="ECO:0000269|PubMed:19622365"
FT                   /id="PRO_0000452214"
FT   ACT_SITE        25
FT                   /evidence="ECO:0000250"
FT   BINDING         26
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /evidence="ECO:0000250"
FT   DISULFID        11..?
FT                   /evidence="ECO:0000305"
FT   DISULFID        21..?
FT                   /evidence="ECO:0000305"
FT   DISULFID        22..?
FT                   /evidence="ECO:0000305"
FT   DISULFID        28..?
FT                   /evidence="ECO:0000305"
FT   DISULFID        38..?
FT                   /evidence="ECO:0000305"
FT   NON_CONS        20..21
FT                   /evidence="ECO:0000305"
FT   NON_TER         48
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   48 AA;  5481 MW;  9DD392852315A403 CRC64;
     NVYQYRKMLQ CAMPNGGPFE CCQTHDNCYG EAEKLKACTS THSSPYFK
//
